NEW YORK (GenomeWeb News) – Martin Madaus will take the CEO and chairman posts at Ortho Clinical Diagnostics upon the closure of The Carlyle Group's acquisition of OCD from Johnson and Johnson, which is expected to be mid-2014, OCD said this week.
Madaus recently was president, chairman, and CEO of Millipore, and is currently executive chairman of Quanterix's board of directors. He also is a director at Carlyle's portfolio companies PPD, Mettler Toledo, and Covidien.
OCD said its current Worldwide President, Eric Compton, will remain with the company after the deal closes.
Genetic Technologies said this week that Alison Mew plans to return to her position as CEO on April 1 after a leave of absence that began in October.
Acting CEO Tom Howitt, the company's chief financial officer and secretary, has tendered his resignation and will depart GTG upon Mew's return. Until Howitt's replacement is found, GTG's current Financial Controller Bronwyn Christie will serve as acting CFO and company secretary.
Eagle Genomics said this week that CEO David Flanders is leaving the company. He will be replaced by company Founder and Chief Operating Officer Abel Ureta Vidal as acting CEO.
During his two years as CEO, Flanders has overseen a round of equity financing, has recruited senior staff members, and helped the business to scale up and develop its ElasticAP platform.
George Church has joined Pathway Genomics' scientific advisory board. A professor of genetics at Harvard Medical School, Church is founder of the Personal Genome Project and director of the Harvard NHGRI Center of Excellence in Genomic Medicine, and he invented the first direct genomic sequencing method in 1984, along with other important genomics innovations.
IncellDx said this week that it has hired Christine Meda as chief business officer.
Meda will oversee the expansion of the company's companion diagnostics team and operations. She has previously served as president of Response Genetics, vice president of women's health at Roche Molecular Diagnostics, director of scientific affairs for Schering AG, and business unit manager at Bio-Rad Laboratories.
Andrew Pecora has resigned from Cancer Genetics' board of directors, effective Feb. 18, the company said in a recent filing with the US Securities and Exchange Commission. Cancer Genetics said Pecora's decision was not the result of a disagreement with the company.
The Mid-Atlantic Permanente Medical Group has named Pim Suwannarat chief of its Department of Genetics, which provides genetic consultation for Kaiser Permanente members in Maryland, Virginia, and Washington, DC.
Suwannarat recently was with Kaiser Permanente Northern California, where she was with the Genetics Department at the San Francisco Kaiser Permanente Medical Center. She trained in pediatrics at Inova Fairfax Hospital for Children and completed her training and board certification in clinical genetics and clinical biochemical genetics at the National Human Genome Research Institute.
The TranSMART Foundation has made several changes to its management team. The foundation has selected Keith Elliston to serve as its CEO and president. Previously, he was the foundation's chief science officer and head of business development. He is also president of Seneca Creek Research.
Elliston will be taking over from co-CEO's Michael Braxenthaler and Brian Athey, who will take on the roles of vice president of industry relations and chief science officer, respectively. Braxenthaler is also president of the Pistoia Alliance and global head of strategic alliances for Roche, while Athey is professor and chair of the department of computational medicine and bioinformatics at the University of Michigan's medical school.
Meanwhile, Kevin Smith, who was previously the executive director of the foundation will now serve as community manager and secretary. He is also director of UM's medical school.
Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.